ReviewBiosensors2026
Optical Biosensors for Blood Coagulation Monitoring: Advantages, Limitations, and Translational Potential.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dynamic monitoring of hemostatic equilibrium is indispensable for clinical safety in high-risk scenarios, while current clinical methods are limited by sample volume, detection speed, and physiological relevance. These shortcomings underscore the demand for novel sensing platforms. Optical biosensors, leveraging label-free detection, rapid response, and multi-level characterization, could serve as a transformative solution for decentralized and point-of-care monitoring. This review systematically summarizes advances in optical coagulation testing, encompassing light transmission aggregometry, laser speckle rheology, optical coherence tomography/elastography, optic-acoustic coupled methods, and fluorescence biosensing. These technologies complementarily capture structural and mechanical and some molecular and cellular dynamics of coagulation, bridging gaps in traditional assays. Despite promising preclinical and clinical correlations, translation barriers persist in lack of standardization of metrics, interference mitigation, and multi-center validation in diverse patient cohorts. Future development of optical biosensing platforms for coagulation testing should focus on modular integration, AI-aided interference correction, and microfluidic miniaturization to realize actionable, real-time coagulation assessment. Optical biosensors hold unparalleled potential to transform hemostatic monitoring from static endpoint testing to dynamic, interpretable evaluation, guiding personalized clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.